{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:06:43Z","timestamp":1767139603425,"version":"build-2238731810"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Idiopathische inflammatorische Myopathien (IIM) sind eine Gruppe seltener und heterogener Systemerkrankungen, die sich nicht nur an der Muskulatur, sondern auch an der Haut, den Gelenken und der Lunge manifestieren. Die Erstsymptome k\u00f6nnen isoliert und variabel auftreten, und so stellt die Diagnosefindung verschiedene Fachgruppen vor Herausforderungen. Da Autoantik\u00f6rper mitunter die einzigen spezifischen Befunde sind, die zur Diagnose und einer angepassten Therapie f\u00fchren, sind grundlegende Kenntnisse \u00fcber diese unabdingbar. In dieser Arbeit erkl\u00e4ren wir verf\u00fcgbare Testsysteme, benennen die klinischen notwendigen Indikationen zur Veranlassung einer Autoantik\u00f6rperdiagnostik, geben Informationen zu Etymologie, Antigenen, Synonymen und Erstbeschreibern, beschreiben die durch Myositisantik\u00f6rper induzierte indirekte Immunfluoreszenz auf HEp-2-Zellen und geben die klinisch-serologischen Assoziationen wieder. Der Abgleich des Autoantik\u00f6rperbefundes mit der klinischen Symptomatik und laborchemischen Befunden erm\u00f6glicht im Sinne einer Plausibilit\u00e4tspr\u00fcfung, falsch positive oder auch falsch negative Laborbefunde zu identifizieren.<\/jats:p>","DOI":"10.1007\/s00393-024-01476-0","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:03:16Z","timestamp":1706691796000},"page":"242-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoantik\u00f6rperdiagnostik bei idiopathisch inflammatorischen Myopathien","Autoantibody diagnostics in idiopathic inflammatory myopathy"],"prefix":"10.1007","volume":"83","author":[{"given":"Robert","family":"Biesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Lindae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Mierau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"1476_CR1","unstructured":"Wiendl H., S.J.e.a., Myositissyndrome, S2k-Leitlinie. in: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie Online: www.dgn.org\/leitlinien (abgerufen am 15. Okt. 2023), 2022."},{"key":"1476_CR2","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.jtauto.2019.100013","volume":"2","author":"ACM Platteel","year":"2019","unstructured":"Platteel\u00a0ACM et\u00a0al (2019) Frequencies and clinical associations of myositis-related antibodies in the Netherlands: a\u00a0one-year survey of all Dutch patients. J\u00a0Transl Autoimmun 2:100013","journal-title":"J Transl Autoimmun"},{"issue":"6","key":"1476_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/BOR.0000000000000548","volume":"30","author":"A Ghirardello","year":"2018","unstructured":"Ghirardello\u00a0A, Doria\u00a0A (2018) New insights in myositis-specific autoantibodies. Curr Opin Rheumatol 30(6):614\u2013622","journal-title":"Curr Opin Rheumatol"},{"key":"1476_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3389\/fimmu.2019.00848","volume":"10","author":"M Mahler","year":"2019","unstructured":"Mahler\u00a0M et\u00a0al (2019) Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol 10:848","journal-title":"Front Immunol"},{"issue":"8","key":"1476_CR5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai\u00a0M, Reichlin\u00a0M (1980) Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo\u20111 antibody system. Arthritis Rheum 23(8):881\u2013888","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1476_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","volume":"5","author":"M Reichlin","year":"1976","unstructured":"Reichlin\u00a0M, Mattioli\u00a0M (1976) Description of a\u00a0serological reaction characteristic of polymyositis. Clin Immunol Immunopathol 5(1):12\u201320","journal-title":"Clin Immunol Immunopathol"},{"issue":"6","key":"1476_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","volume":"46","author":"Z Betteridge","year":"2007","unstructured":"Betteridge\u00a0Z et\u00a0al (2007) Anti-synthetase syndrome: a\u00a0new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 46(6):1005\u20131008","journal-title":"Rheumatology"},{"issue":"7","key":"1476_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","volume":"78","author":"J Damoiseaux","year":"2019","unstructured":"Damoiseaux\u00a0J et\u00a0al (2019) Clinical relevance of HEp\u20112 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 78(7):879\u2013889","journal-title":"Ann Rheum Dis"},{"key":"1476_CR9","doi-asserted-by":"crossref","unstructured":"Graf M et\u00a0al (2022) SIGLEC1 enables straightforward assessment of type\u00a0I interferon activity in idiopathic inflammatory myopathies. RMD Open 8(1)","DOI":"10.1136\/rmdopen-2021-001934"},{"issue":"2","key":"1476_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3899\/jrheum.221067","volume":"50","author":"NJ McHugh","year":"2023","unstructured":"McHugh\u00a0NJ (2023) Ro52, myositis, and interstitial lung disease. J\u00a0Rheumatol 50(2):161\u2013163","journal-title":"J Rheumatol"},{"issue":"e523","key":"1476_CR11","first-page":"20","volume":"94","author":"A Meyer","year":"2015","unstructured":"Meyer\u00a0A et\u00a0al (2015) In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine 94(e523):20","journal-title":"Medicine"}],"updated-by":[{"DOI":"10.1007\/s00393-024-01492-0","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000}}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01476-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:05:33Z","timestamp":1711533933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01476-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01476-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"20 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00393-024-01492-0","URL":"https:\/\/doi.org\/10.1007\/s00393-024-01492-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Lindae ist bei EUROIMMUN, einem Unternehmen, das diagnostische Tests und Ger\u00e4te herstellt, angestellt. A. Lindae hat in Zusammenhang mit dem vorliegenden Beitrag keinen potenziellen oder tats\u00e4chlichen finanziellen Gewinn erzielt. R.\u00a0Biesen, U.\u00a0Schneider und R.\u00a0Mierau geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}